Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
NCT00380276
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
1000
Enrollment
INDUSTRY
Sponsor class
Stopped
Myriad has discontinued the development of Flurizan.
Conditions
Alzheimer's Disease
Interventions
DRUG:
MPC-7869
Sponsor
Myrexis Inc.